Top Female Sexual Dysfunction Treatment Companies

Global Female Sexual Dysfunction Treatment Market size was valued at USD 542.97 Million in 2024 and is poised to grow from USD 613.55 Million in 2025 to USD 1631.09 Million by 2033, growing at a CAGR of 13% during the forecast period 13%.

The Female Sexual Dysfunction (FSD) Treatment market is becoming increasingly competitive, with key pharmaceutical companies focusing on product innovation, regulatory approvals, and global expansion. Major players are diversifying their portfolios by developing both hormonal and non-hormonal therapies to address a wide range of patient needs and medical profiles. For instance, companies like Sprout Pharmaceuticals and AMAG Pharmaceuticals have strengthened their positions through targeted treatments such as Flibanserin and Bremelanotide, approved specifically for Hypoactive Sexual Desire Disorder (HSDD). Regional players, especially in Asia and Latin America, are gaining traction by offering affordable generics and over-the-counter options tailored for emerging markets. Strategic collaborations—such as licensing agreements and co-marketing deals between pharmaceutical firms and healthcare providers—are enhancing market reach and patient accessibility. Meanwhile, innovation in drug delivery methods, such as transdermal and intravaginal therapies, is emerging as a key differentiator, helping companies address safety concerns and improve patient adherence in a competitive landscape. 'Millendo Therapeutics (Tempest Therapeutics)', 'AbbVie', 'TherapeuticsMD', 'Sorrento Therapeutics', 'Palatin Technologies', 'Eureka Therapeutics', 'HRA Pharma', 'NantKwest', 'Bristol-Myers Squibb', 'Pfizer', 'Allergen', 'Bayer', 'Neurotrope', 'AMAG Pharmaceuticals', 'Sprout Pharmaceuticals, Inc.', 'Mayne Pharma Group Limited', 'Millicent Pharma Ltd. (Endoceutics, Inc)', 'Duchesnay Pharmaceutical Group Inc.', 'Freya Pharma Solutions B.V.', 'Acerus Pharmaceuticals Corporation'

The growing awareness of women's health issues and the rising prevalence of conditions such as menopause-related symptoms, hormonal imbalances, and stress-induced dysfunctions are fueling demand for Female Sexual Dysfunction (FSD) treatment. As modern lifestyles contribute to increased physical and mental health challenges, healthcare systems and providers are integrating FSD solutions into broader wellness and preventive care programs. This is particularly evident in sectors like corporate wellness, reproductive health, and gynecology, where addressing sexual health is becoming a priority for overall quality of life and long-term well-being.

Telehealth and digital therapeutics are being employed more and more in FSD treatment. These platforms offer discreet entry to consultation, therapy, and prescription, helping to circumvent geographic and stigma barriers. Convenience of virtual care equals patient expectations of privacy and flexibility, and helps to monitor progress and modify treatments more easily.

North America dominates the global Female Sexual Dysfunction (FSD) Treatment market, driven by high healthcare expenditure, strong regulatory oversight, and growing awareness of women’s health issues. The region benefits from early adoption of FDA-approved drugs such as Flibanserin and Bremelanotide, along with the presence of key pharmaceutical players and a well-established healthcare infrastructure. Ongoing research, active clinical trials, and increasing public acceptance of FSD as a legitimate medical concern further reinforce North America's leadership in the space.